David Feltquate, MD, PhD

Advisor

David Feltquate is an Advisor at Raven. Prior to joining Raven, he was most recently CMO at iTeos Therapeutics and before this, he was CMO at Palleon Pharmaceuticals. Earlier in his career, David was the Global Head of Hematology Development and Chair of the Precision Medicine Leadership Team at Novartis. Before this, he held numerous leadership positions at BMS including Head of Oncology Early Clinical Development and Development Leader for Ipilimumab/​Nivolumab Life Cycle Management. As the Nivolumab Clinical Head, David was responsible for the clinical development of the first PD‑1 inhibitor from proof of concept through initial registration in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. He is also currently a non-Executive Board Member at Nerviano Medical Sciences – US. David earned a BS in biology from MIT and an MD/​PhD in Immunology from the University of Massachusetts Medical School. He completed Internal Medicine training and was Chief Resident at Dartmouth Hitchcock Medical Center and Medical Oncology training at the Memorial Sloan-Kettering Cancer Center.